WeightWatchers files for bankruptcy — These GLP-1 firms want to help you meet your goals
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change.
As GLP-1 firms continue to bulk up, WeightWatchers (WW) is stepping off the scale.
The points-system-based weight loss program filed for bankruptcy on May 6, with its premarket value plummeting 52% by Wednesday morning.
A growing debt burden forced the company to scale back operations, but current members were assured they wouldn't be affected by the filing. A reorganization plan is expected within 40 days, according to a statement released Tuesday.
Advertisement
'As the conversation around weight shifts toward long-term health, our commitment to delivering the most trusted, science-backed, and holistic solutions — grounded in community support and lasting results — has never been stronger, or more important,' said Tara Comonte, Chief Executive Officer of WW.
Comonte suggested that the filing was supported by lenders, who are committed to helping the company shed its $1.15 billion debt, appeal to new customers, and innovate in the rapidly evolving weight management landscape — a space that is currently swamped with competitive GLP-1 solutions.
WeightWatchers has struggled to maintain subscriptions as people turn to popular medications like Ozempic, Mounjaro, and Wegovy.
Originally used to treat diabetes, GLP-1s have become an attractive option for those looking to suppress hunger and shed pounds fast.
Advertisement
The company found some relief after adding GLP-1 obesity treatment offerings in 2023, but still hasn't strayed from the more traditional approach to weight loss, focusing on food intake and behavioral changes. On Tuesday's call, Comonte acknowledged the surge of GLP-1 usage, but added that they are 'a medication, not a miracle.'
According to a recent Kaiser Family Foundation poll, roughly 6% of U.S. adults are currently taking GLP-1 for weight loss, and the effects are impressive. A 2022 study found that people who received weekly semaglutide injections lost an average of about 15 pounds after three months.
Over the last couple of years, some insurance providers have announced they would no longer offer coverage for weight-loss medications like Ozempic. In response, some have begun turning to telehealth companies like Ro, G-Plans Direct, and Remedy Meds — all of which offer virtual prescriptions for different weight-loss drugs, as well as other health services.
It's a tough time to compete with new weight-loss drugs; different payment plans are available, treatments are more accessible for people without insurance, and telehealth companies are offering easier paths towards getting a prescription. Still, the GLP-1 landscape can be difficult to navigate.
Advertisement
Here's the skinny on the telehealth companies worth considering.
Looking for a headline-worthy haul? Keep shopping Post Wanted.
This article was written by Miska Salemann, New York Post Commerce Writer/Reporter. As a health-forward member of Gen Z, Miska seeks out experts to weigh in on the benefits, safety and designs of both trending and tried-and-true fitness equipment, workout clothing, dietary supplements and more. Taking matters into her own hands, Miska intrepidly tests wellness products, ranging from Bryan Johnson's Blueprint Longevity Mix to home gym elliptical machines to Jennifer Aniston's favorite workout platform – often with her adorable one-year old daughter by her side. Before joining The Post, Miska covered lifestyle and consumer topics for the U.S. Sun and The Cannon Beach Gazette.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
This $450 iPad Pro is proof that you can have it all
Discover startups, services, products and more from our partner StackCommerce. New York Post edits this content, and may be compensated and/or receive an affiliate commission if you buy through our links. TL;DR: You do not want to miss getting this near-mint 3rd Gen iPad Pro for just $449.99 (reg. $849). Want the power of a laptop, the convenience of a tablet, and a price that doesn't make you flinch? Meet the grade-A refurbished Apple iPad Pro 12.9″ (3rd Gen, 2018)—yours right now for just $449.99 (regularly $849). This iPad isn't just about good looks (though with its edge-to-edge Liquid Retina display, it definitely has them). It's powered by Apple's mighty A12X Bionic chip, which means fast, fluid performance whether you're editing 4K video, sketching your next big idea, or breezing through emails. The 12.9″ display is seriously impressive, featuring ProMotion technology for up to 120Hz refresh rate, True Tone for more comfortable viewing, and a wide P3 color gamut that makes everything pop. Whether you're working on client projects, binge-watching your favorite series, or just admiring your own digital artwork, it all looks stunning here. And because this device is Grade-A refurbished, it arrives in near-mint condition—clean, tested, and ready to go. It's fully compatible with the 2nd Gen Apple Pencil (not included), has a 12MP rear camera with 4K video support, and weighs just 1.39 pounds—perfect for tossing in a tote and heading out the door. This isn't just a tablet. It's your 256GB digital sketchbook, mobile workstation, personal theater, and productivity sidekick—all rolled into one beautifully engineered package. So yes, you can have it all. High performance. Gorgeous display. Trusted Apple quality. And a price that doesn't come with monthly payments or heart palpitations. But like all good things, this deal won't stick around forever. Get a like-new iPad Pro for just $449.99 (regularly $849) while you still can. StackSocial prices subject to change.
Yahoo
4 hours ago
- Yahoo
MLB insider sheds light on likelihood of Milwaukee Brewers trading Freddy Peralta
The Milwaukee Brewers have earned a reputation for trading high-end pitchers when they are nearing the end of their contracts. With the MLB trade deadline just a month away, All-Star pitcher Freddy Peralta has popped up in trade rumors. Jon Heyman of the New York Post writes that despite immense interest from around the league, it's a 'long shot' that the Brewers trade Peralta. That's because Peralta's contract is extremely valuable. Advertisement Related: Insider explains how Brewers' latest trade could impact deadline Freddy Peralta contract (Spotrac): $8 million salary in 2025, $8 million club option for 2026 season While he is only under contract through 2026, his salary is a bargain for his production. While he last earned an All-Star selection in 2021, Perala entered MLB games today ranked 15th in ERA. He is also in the top 25 for strikeouts and WHIP this season. For context regarding Peralta's $8 million salary, there are 67 starting pitchers with a higher base salary than his in 2025. Next season, Peralta will rank 57th in starting pitcher salaries and that's before extensions and new deals signed this upcoming offseason. Related: Milwaukee Brewers owner viewed as potential successor to Rob Manfred Freddy Peralta stats (ESPN): 2.76 ERA, 1.11 WHIP, 90-34 K-BB in 88 innings Advertisement The contract and production are too valuable for the Brewers to move, especially with the club battling for a wild card spot this season. While it's at least possible Milwaukee could revisit a trade this winter, there are no indications right now that Peralta is available. Related Headlines
Buzz Feed
19 hours ago
- Buzz Feed
Lizzo Talks About Using Ozempic For Weight Loss
There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.
